Synapse - Andrew Zelenetz

Search Within

Andrew D Zelenetz

Results (767)

Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience

Meeting Abstract

Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
Blood (2023)

Fulltext@MSK | Save

Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience

Meeting Abstract

Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2023)

Fulltext@MSK | Save

Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)

Meeting Abstract

Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory marginal zone lymphoma: Results from phase 1/2 BRUIN study

Meeting Abstract

Patel, K.; Vose, J. M.; Nasta, S. D.; Brown, J. R.; Maddocks, K. J.; Woyach, J. A.; Shah, N. N.; Fakhri, B.; Tessoulin, B.; Ma, S.; more...
Blood (2023)

Fulltext@MSK | Save

Early results indicate acceptable safety and promising efficacy of venetoclax in combination with pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma

Meeting Abstract

Zelenetz, A. D.; Diefenbach, C. S.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Troy-Barnes, E.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes in mantle cell lymphoma with central nervous system involvement - A dual center study

Meeting Abstract

McLaughlin, N.; Joseph, A.; Wang, Y. C.; Pederson, L. D.; Geyer, S. M.; Witzig, T. E.; Zelenetz, A. D.; Villasboas, J. C. C.; Scordo, M.; Hamlin, P. A.; more...
Blood (2023)

Fulltext@MSK | Save

A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma

Meeting Abstract

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
Blood (2023)

Fulltext@MSK | Save

Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study

Meeting Abstract

Falchi, L.; Okwali, M.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Palomba, M. L.; Kumar, A.; Torka, P.; more...
Blood (2023)

Fulltext@MSK | Save

Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades

Meeting Abstract

Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
Blood (2023)

Fulltext@MSK | Save